

Information Regarding Clinical Trial

| | |
|------------------------------------|---|
| Title | DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors |
| Protocol Number | S1609 |
| Sponsor | SWOG |
| Investigator | J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703 |
| Study Related Phone Numbers | 479-587-1700 (24 hours) |
| Key Points for Study | Ipilimumab with Nivolumab treatments Tissue required Must have progressed following at least one line of standard tx and there must not be other approved therapy available to prolong overall survival Patients may have received either prior anti-CTLA4 or other prior anti-PD-1/antiPD-L1 therapy. NOT BOTH No grade 3 or higher immune related adverse events with prior immunotherapy are not eligible. |